Conference Proceedings
Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results
Rathika Kandasamy, Marios Constantinou, Sophie L Rogers, Sukhpal Singh Sandhu, Sanjeewa Wickremasinghe, Salmaan Al-Qureshi, Lyndell L Lim
BRITISH JOURNAL OF OPHTHALMOLOGY | BMJ PUBLISHING GROUP | Published : 2019
Abstract
AIM: To report the 6-month results of a clinical trial that compared intravitreous bevacizumab (BVB) 1.25 mg versus triamcinolone acetonide (TA) 4 mg when administered as an adjunct during cataract surgery to patients with diabetic macular oedema (DMO). METHODS: Prospective, double-masked, single-centre (Royal Victorian Eye and Ear Hospital, Melbourne) clinical trial. Patients with visually significant cataract and centre-involving DMO (either current or prior) were randomised (1: 1) to receive either intravitreous BVB 1.25 mg or TA 4 mg at the time of cataract surgery and if required at review. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central macular thi..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC) Early Career Fellowships
Funding Acknowledgements
This study has received funding from the Royal Victorian Eye and Ear Hospital Grants Program 2013-2014 (Melbourne), Diabetes Australia Research Program Grant 2015 (Canberra), Ramaciotti Health Investment Grant 2016 (Sydney) and the Hazel Jean Eastham Bequest (Melbourne). Centre for Eye Research Australia receives operational infrastructure support from the Victorian government. Associate Professor Lim (GNT 1109330) and Dr Wickremasinghe (GNT 1128343) are supported by National Health and Medical Research Council (NHMRC) Early Career Fellowships. The sponsor or funding organisations had no role in the design or conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript or decision to submit the manuscript for publication. Dr Kandasamy and Associate Professor Lim had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.